| 2024-01-02 | +63.2% | legal | SEC EDGAR | VNRX 8-K: 8.01 (SEC Filing) |
| 2025-10-09 | -25.4% | news | Seeking Alpha | VolitionRx proposes underwritten public offering of common stock, common stock warrants |
| 2025-10-09 | -25.4% | news | TradingKey | VNRX|VolitionRX Ltd|Price:0.139|Chg%:-0.00 - TradingKey |
| 2025-10-10 | -23.3% | news | Seeking Alpha | VolitionRx announces pricing of $6M underwritten public offering of common stock and common stock warrants |
| 2025-10-10 | -23.3% | news | GuruFocus | VolitionRx (VNRX) Sets Pricing for Public Offering of Shares and Warrants - GuruFocus |
| 2026-02-25 | +21.1% | news | Stock Titan | Simple blood test finds most cat lymphomas, unlocks $5M for VolitionRx - Stock Titan |
| 2026-04-02 | -16.0% | legal | Minichart | VolitionRx Limited (VNRX) 8-K SEC Filing March 31, 2026: Company Details, Address, and Stock Information - Minichart |
| 2026-04-01 | -15.9% | earnings | Moby | VolitionRx Limited Q4 2025 Earnings Call Summary |
| 2026-04-01 | -15.9% | earnings | Seeking Alpha | VolitionRx anticipates France routine Nu.Q Cancer use by Q4 2026 while targeting 25%-30% 2026 cash OpEx reduction |
| 2026-04-01 | -15.9% | earnings | Seeking Alpha | VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript |
| 2026-04-01 | -15.9% | news | Seeking Alpha | VolitionRX reports FY results |
| 2026-04-01 | -15.9% | news | Stock Titan | VolitionRx (NYSE: VNRX) wins approval for major share issue and reverse split - Stock Titan |
| 2026-01-08 | +15.9% | expansion | Seeking Alpha | VolitionRx secures $2M financing through amended securities agreement; shares up |
| 2026-01-08 | +15.9% | legal | SEC EDGAR | VNRX 8-K: 1.01, 3.02 (SEC Filing) |
| 2026-01-08 | +15.9% | news | Investing.com | Volitionrx stock soars after feline cancer test shows high accuracy - Investing.com |
| 2026-01-08 | +15.9% | expansion | MSN | VolitionRx secures $2M financing through amended securities agreement; shares up - MSN |
| 2022-05-11 | -12.9% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2025-08-14 | +12.3% | earnings | Seeking Alpha | VolitionRX reports Q2 results |
| 2025-08-14 | +12.3% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2025-04-02 | +11.8% | news | Intellectia AI | VNRX Forecast — Price Prediction for 2026. Should I Buy VNRX? - Intellectia AI |
| 2026-04-23 | -11.5% | news | PR Newswire | VolitionRx Announces Acceptance of Compliance Plan by NYSE American |
| 2026-04-23 | -11.5% | legal | Seeking Alpha | VolitionRx secures NYSE American compliance plan approval |
| 2026-04-23 | -11.5% | legal | SEC EDGAR | VNRX 8-K: 3.01, 8.01 (SEC Filing) |
| 2026-04-23 | -11.5% | news | Stock Titan | VolitionRx shares stay on NYSE as exchange accepts compliance plan - Stock Titan |
| 2026-04-23 | -11.5% | news | Stock Titan | VolitionRx (NYSE: VNRX) wins NYSE American time to fix listing - Stock Titan |
| 2025-09-29 | +11.5% | analyst | GuruFocus | VNRX Stock: Analyst Maintains 'Buy' Rating with $5.00 Price Targ - GuruFocus |
| 2026-04-20 | -11.3% | expansion | PR Newswire | Volition Launches rNuQ™ Webshop Broadening Product Range |
| 2026-02-10 | -11.0% | news | Stock Titan | VolitionRx nears 100 Nu.Q Discover clients, extends reach to Japan - Stock Titan |
| 2023-11-14 | -10.6% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2024-09-30 | +10.5% | legal | SEC EDGAR | VNRX 8-K: 5.02 and (SEC Filing) |
| 2025-07-03 | -10.4% | news | Seeking Alpha | VolitionRx files to sell 23.44M shares of common stock by selling shareholders |
| 2024-05-13 | -10.0% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2025-11-14 | -9.9% | earnings | Seeking Alpha | VolitionRx signals transformative period as new partnerships target $85M APS market and drive 32% revenue growth |
| 2025-11-14 | -9.9% | earnings | Seeking Alpha | VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript |
| 2025-05-15 | -9.8% | earnings | Seeking Alpha | VolitionRX Q1 2025 Earnings Preview |
| 2025-05-15 | -9.8% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2024-03-19 | -9.8% | legal | SEC EDGAR | VNRX 8-K: 8.01 and (SEC Filing) |
| 2024-11-14 | -9.1% | earnings | Seeking Alpha | VolitionRX reports Q3 results |
| 2024-11-14 | -9.1% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2025-11-13 | -9.0% | earnings | Seeking Alpha | VolitionRX reports Q3 results |
| 2025-11-13 | -9.0% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2025-11-13 | -9.0% | legal | SEC EDGAR | VNRX 8-K: 1.01 and (SEC Filing) |
| 2025-11-13 | -9.0% | earnings | Yahoo Finance | VolitionRX Ltd (VNRX) Q3 2025: Everything You Need to Know Ahead of Earnings - Yahoo Finance |
| 2026-04-17 | -8.4% | legal | SEC EDGAR | VNRX 8-K: 8.01 (SEC Filing) |
| 2026-04-17 | -8.4% | news | Stock Titan | VolitionRx (VNRX) to execute 1-for-20 reverse stock split on April 28, 2026 - Stock Titan |
| 2025-05-16 | -8.3% | news | Seeking Alpha | VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances |
| 2025-05-16 | -8.3% | earnings | Seeking Alpha | VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript |
| 2025-05-16 | -8.3% | earnings | Seeking Alpha | VolitionRX GAAP EPS of -$0.06, revenue of $0.25M |
| 2022-03-29 | +8.1% | legal | SEC EDGAR | VNRX 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-10-08 | -8.0% | news | Seeking Alpha | VolitionRx Limited (VNRX) Discusses Beyond The Genome: Measuring Epigenetic Modifications Across Matrices For Biomarker And Drug Discovery Transcript |
| 2022-05-20 | -7.8% | legal | SEC EDGAR | VNRX 8-K: 1.01 and (SEC Filing) |
| 2024-11-08 | +7.5% | news | Seeking Alpha | VolitionRx files for common stock, warrants, and units for offering price of $1B |
| 2025-11-17 | +7.5% | executive | Investing.com | Reynolds, Volitionrx CEO, buys $7,000 in VNRX stock - Investing.com |
| 2021-05-11 | +7.3% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2024-09-27 | +7.1% | legal | SEC EDGAR | VNRX 8-K: 5.02 (SEC Filing) |
| 2023-02-21 | -7.0% | legal | SEC EDGAR | VNRX 8-K: 1.01, 2.02, 8.01 (SEC Filing) |
| 2025-08-05 | +7.0% | news | Stock Titan | VolitionRx (VNRX) insider: 18,341 RSUs settled, shares retained for tax - Stock Titan |
| 2024-11-15 | -7.0% | earnings | Seeking Alpha | VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript |
| 2025-03-31 | -6.7% | news | Seeking Alpha | VolitionRX reports FY results |
| 2025-03-31 | -6.7% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2024-12-09 | -6.7% | legal | SEC EDGAR | VNRX 8-K: 1.01, 8.01 (SEC Filing) |
| 2023-03-15 | -6.6% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2022-08-16 | -6.4% | legal | SEC EDGAR | VNRX 8-K: 5.02 and (SEC Filing) |
| 2024-11-06 | +6.4% | legal | SEC EDGAR | VNRX 8-K: 5.02 and (SEC Filing) |
| 2025-08-15 | +6.4% | earnings | Seeking Alpha | VolitionRx Limited 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-15 | +6.4% | earnings | Seeking Alpha | VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript |
| 2026-03-26 | +6.2% | analyst | PR Newswire | Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference |
| 2026-03-26 | +6.2% | news | Stock Titan | A blood test before lung surgery helped flag higher-risk patients - Stock Titan |
| 2025-11-07 | -6.2% | legal | SEC EDGAR | VNRX 8-K: 1.01 and (SEC Filing) |
| 2024-08-15 | +6.1% | earnings | Seeking Alpha | VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript |
| 2024-08-14 | +6.1% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2025-04-01 | -6.1% | news | Seeking Alpha | VolitionRx outlines 2025 licensing goals and targets cash neutrality with strategic expansions |
| 2025-04-01 | -6.1% | earnings | Seeking Alpha | VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript |
| 2025-04-01 | -6.1% | news | Intellectia AI | VNRX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2022-06-14 | -5.8% | legal | SEC EDGAR | VNRX 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-02-20 | -5.3% | legal | SEC EDGAR | VNRX 8-K: 3.02 and (SEC Filing) |
| 2026-01-30 | +5.1% | news | Stock Titan | VolitionRx moves to bring Nu.Q lung cancer test to French patients - Stock Titan |
| 2024-04-26 | -4.8% | legal | SEC EDGAR | VNRX 8-K: 5.02, 5.03 (SEC Filing) |
| 2025-11-10 | -4.6% | legal | SEC EDGAR | VNRX 8-K: 1.01 and (SEC Filing) |
| 2026-03-19 | -4.5% | news | Stock Titan | VolitionRx (VNRX) CSO uses 5,310 shares to cover tax bill - Stock Titan |
| 2026-03-19 | -4.5% | legal | Stock Titan | Tax withholding reduces VolitionRx (NYSE: VNRX) secretary’s share count - Stock Titan |
| 2024-03-28 | +4.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2023-06-05 | +3.9% | legal | SEC EDGAR | VNRX 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-04-22 | -3.8% | legal | SEC EDGAR | VNRX 8-K: 1.01, 1.02 (SEC Filing) |
| 2024-12-06 | +3.4% | news | Seeking Alpha | VolitionRx announces pricing of up to $1.9M registered direct offering |
| 2023-05-10 | -3.4% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2021-11-10 | +3.3% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2025-10-14 | -3.1% | legal | SEC EDGAR | VNRX 8-K: 1.01, 2.02, 7.01 (SEC Filing) |
| 2025-12-11 | -3.1% | legal | SEC EDGAR | VNRX 8-K: 5.02 (SEC Filing) |
| 2025-03-26 | -3.0% | legal | SEC EDGAR | VNRX 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-03-26 | -3.0% | news | Stock Titan | VolitionRx Directors Lead $2.3M Investment: What This Insider Backing Reveals - Stock Titan |
| 2021-08-11 | +3.0% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2022-11-14 | +2.9% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2024-03-25 | +2.8% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2026-03-25 | -2.8% | news | Stock Titan | VolitionRx to outline 2025 results and milestones on April 1 - Stock Titan |
| 2026-03-25 | -2.8% | news | Stock Titan | Blood test detects 95% of stage I and II cancers in blinded study - Stock Titan |
| 2026-03-25 | -2.8% | news | parameter.io | VolitionRx Limited (VNRX) Stock: Rallies on Promising Multi-Cancer Early Detection Breakthrough - parameter.io |
| 2023-06-30 | -2.7% | legal | SEC EDGAR | VNRX 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-10-15 | -2.7% | news | Investing.com | Still buys VolitionRx (VNRX) shares and warrants for $24,518 - Investing.com |
| 2024-07-03 | -2.6% | legal | SEC EDGAR | VNRX 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2021-05-16 | +2.6% | analyst | Benzinga | VolitionRX Analyst Ratings and Price Targets | AMEX:VNRX - Benzinga |
| 2023-12-05 | -2.4% | legal | SEC EDGAR | VNRX 8-K: 8.01 and (SEC Filing) |
| 2022-08-02 | -2.4% | legal | SEC EDGAR | VNRX 8-K: 1.01, 2.02, 8.01 (SEC Filing) |
| 2025-03-11 | -2.1% | news | Stock Titan | Major Breakthrough: Volition's Blood Test Could Transform Lung Cancer Screening - First Patient Enrolled - Stock Titan |
| 2024-08-12 | -2.1% | legal | SEC EDGAR | VNRX 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-03-06 | +2.0% | news | Stock Titan | Automated cancer screening test set for Japan’s 7M pet dogs - Stock Titan |
| 2026-04-03 | -1.9% | earnings | GuruFocus.com | VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... |
| 2026-03-18 | +1.6% | analyst | GuruFocus | VNRX Receives Unchanged 'Buy' Rating from D. Boral Capital | VNR - GuruFocus |
| 2026-03-18 | +1.6% | news | Stock Titan | New liquid biopsy from VolitionRx finds 49 of 49 cancers in early study - Stock Titan |
| 2026-03-18 | +1.6% | news | Blockonomi | VolitionRx (VNRX) Stock Soars 70% on Revolutionary Cancer DNA Discovery - Blockonomi |
| 2022-09-01 | -1.6% | analyst | TradingView | VNRX Forecast — Price Target — Prediction for 2027 - TradingView |
| 2022-08-10 | -1.6% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2022-08-18 | +1.6% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for VolitionRX Limited (VNRX) - Zacks Investment Research |
| 2026-03-31 | +1.6% | earnings | Associated Press | VolitionRX: Q4 Earnings Snapshot |
| 2026-03-31 | +1.6% | news | PR Newswire | VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update |
| 2026-03-31 | +1.6% | earnings | GuruFocus.com | VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of Earnings |
| 2026-03-31 | +1.6% | legal | PR Newswire | VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium |
| 2026-03-31 | +1.6% | legal | Seeking Alpha | VolitionRx Limited secures 2M non-dilutive funding from Belgian agencies |
| 2026-03-31 | +1.6% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2026-03-31 | +1.6% | earnings | Stock Titan | Volition says its tests are nearing hospital use in lung cancer and sepsis - Stock Titan |
| 2026-03-31 | +1.6% | news | Stock Titan | Belgian agencies give VolitionRx €2M to advance tests for poorer countries - Stock Titan |
| 2026-03-31 | +1.6% | earnings | Investing.com | Volitionrx Ltd earnings beat, revenue fell short of estimates - Investing.com |
| 2023-08-14 | -1.0% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2025-08-04 | -1.0% | news | Seeking Alpha | VolitionRx prices $1.2M registered direct offering |
| 2025-08-04 | -1.0% | legal | SEC EDGAR | VNRX 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-03-21 | -0.8% | news | Stock Titan | Revolutionary Cancer Detection: Volition's Nu.Q Test Targets 21 Cancer Types with Single Blood Draw - Stock Titan |
| 2021-06-22 | -0.7% | legal | SEC EDGAR | VNRX 8-K: 5.02, 5.07 (SEC Filing) |
| 2021-06-22 | -0.7% | news | Insider Monkey | Is VolitionRX (VNRX) A Good Stock To Buy? - Insider Monkey |
| 2022-11-25 | +0.7% | legal | SEC EDGAR | VNRX 8-K: 5.02 (SEC Filing) |
| 2026-02-09 | -0.6% | news | Seeking Alpha | VolitionRx receives NYSE non-compliance notice |
| 2026-02-09 | -0.6% | legal | SEC EDGAR | VNRX 8-K: 3.01, 8.01 (SEC Filing) |
| 2026-02-09 | -0.6% | news | Stock Titan | VolitionRx stock gets 'below compliance' tag after NYSE warning - Stock Titan |
| 2026-01-20 | +0.3% | news | Stock Titan | Dog cancer blood test expands to all 50 states and parts of Asia - Stock Titan |
| 2026-03-30 | +0.2% | news | PR Newswire | Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients |
| 2022-03-30 | -0.1% | legal | SEC EDGAR | VNRX 8-K: 2.02 and (SEC Filing) |
| 2026-03-03 | -0.1% | legal | Stock Titan | Tax withholding on VolitionRx (VNRX) shares for officer via RSU settlement - Stock Titan |